ALK and non-small cell lung carcinoma: Thus, ensartinib has been evaluated in treatment-naïve ALK-positive NSCLC patients compared with other ALKIs, and has shown promising results as first-line systemic therapy, but the results remain to be confirmed by additional future studies.